The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
The broad goal of this grant, under the UG3/UH3 Exploratory/Developmental phased initiative, is to foster the discovery and development of safe, nontoxic, and effective natural products for cancer interception and prevention. The grant program outlines specific phases with distinct purposes: The UG3 phase aims to select clinical targets, develop and validate assays for bioactivity and toxicity screening, while the UH3 phase focuses on screening libraries, structure elucidation, full-scale characterization, efficacy testing, and the development of screened agents.